Nasolabial Folds: Filler Choices, FDA-Approved Options, and What Filler Cannot Fix

When you look in the mirror or inspect candid photographs, do you notice deep diagonal shadows extending from the outer corners of your nose down toward the corners of your mouth? Colloquially termed smile lines or laugh lines, nasolabial folds (NLFs) are among the very first facial landmarks people notice as they enter their thirties and forties.

Because these folds are prominent and cosmetically visible, they are among the most frequently treated anatomical areas in modern aesthetic medicine. However, widespread marketing often oversimplifies what nasolabial folds are and how they should be corrected.

Patients are routinely told that a single syringe of filler directly in the crease will "erase" the line. In clinical reality:

1. The nasolabial fold is the ultimate regulatory proving ground of US aesthetic medicine. While injectables in areas like the tear troughs or jawline are often off-label, the nasolabial fold is the most on-label treatment area in soft-tissue filler history: 36 approval records across 16 distinct Premarket Approval (PMA) families name correction of moderate-to-severe nasolabial folds among their FDA-approved indications.
2. Treatment is a diagnosis problem, not a line-filling routine. Nasolabial folds are rarely caused by a wrinkle in the skin itself. They are structural boundary lines formed by midface fat descent, maxillary bone resorption, and skin laxity. In many patients, injecting filler directly into the crease creates an unnatural, puffy "snout" or "pillow face," whereas restoring midface cheek support above the fold produces a superior, natural lift.
3. The region houses critical vascular danger zones. The facial artery courses within millimeters of the nasolabial crease, running from the mandibular border past the oral commissure up to the nasal ala. Inadvertent intravascular injection here can cause immediate tissue necrosis of the nasal wing, upper lip ulceration, or retrograde embolic blindness.
4. Filler has a hard ceiling. When fold prominence is driven primarily by true tissue laxity, jowling, and SMAS descent, adding more filler merely weighs down an already heavy lower face. At that stage, surgical lifting or energy-based tightening is the only honest solution.

Here is the comprehensive, evidence-based clinical guide to nasolabial fold treatment: how folds form, which fillers hold real FDA approvals, how top injectors choose between direct filling and midface support, the exact anatomical millimeter distances protecting your vascular safety, realistic multi-year cost math, and when surgery is the right choice.

---

Direct Answer: What Actually Works for Nasolabial Folds?

Hyaluronic acid (HA) dermal filler—placed either directly into the deep pyriform space/subdermal fold or strategically within the midface malar fat compartments—is the evidence-based first-line treatment for volume-dominated nasolabial folds, typically requiring 1 to 2 syringes ($650 to $1,900 total) and lasting 9 to 18 months.

However, selecting the right treatment requires understanding what is driving your specific fold:

• Volume-Loss-Dominated Folds: If your fold deepened because of youthful fat pad deflation or bone recession around the piriform aperture, HA fillers (such as Juvéderm, Restylane, or RHA) or biostimulators (such as Sculptra or Radiesse) restore the structural foundation with high patient satisfaction.
• Laxity-Dominated Folds: If your fold is formed by a heavy, sliding cheek fat pad resting against a fixed muscular retaining ligament in the presence of severe skin sagging, adding direct filler to the fold will flatten your facial contours and worsen lower-face heaviness. These patients require energy-based skin tightening, thread lifts, or a deep plane surgical facelift.
• Surface Skin Etching: If your fold consists of fine, superficial crease lines in the dermis from repetitive dynamic smiling and photoaging, fractional laser resurfacing or superficial micro-droplet HA is required, rather than deep structural boluses.

                    ┌─────────────────────────────────────────┐
                    │      NASOLABIAL FOLD PRESENTATION       │
                    └────────────────────┬────────────────────┘
                                         │
          ┌──────────────────────────────┼──────────────────────────────┐
          ▼                              ▼                              ▼
┌───────────────────┐          ┌───────────────────┐          ┌───────────────────┐
│   VOLUME LOSS     │          │    SKIN LAXITY    │          │  DERMAL ETCHING   │
│ (Deep Pyriform /  │          │ (Malar Descent /  │          │ (Superficial Skin │
│  Maxillary Notch) │          │  Heavy Jowling)   │          │  Dynamic Crease)  │
└─────────┬─────────┘          └─────────┬─────────┘          └─────────┬─────────┘
          │                              │                              │
          ▼                              ▼                              ▼
• Prominent shadow at ala      • Fold overhangs crease        • Line visible when relaxed
• Flattened upper cheek        • Excess skin pinch >1.5 cm    • Thin, sun-damaged skin
• Bone recession at base       • Blunting of jawline          • Muscle-tethered crease
          │                              │                              │
          ▼                              ▼                              ▼
    [DERMAL FILLER]            [LIFTING / TIGHTENING]         [LASER / SKIN RESURFACING]
 • Midface malar support        • Deep plane facelift          • Fractional CO2 / Erbium
 • Deep pyriform bolus          • SMAS plication / Lift        • Superficial micro-HA
 • 1–2 syringes ($650–$1.9k)    • Non-surgical ultrasound      • Chemical reconstruction

---

Why Nasolabial Folds Deepen: Anatomy of the Smile Line

To understand why simple skincare or superficial treatments cannot erase a nasolabial fold, one must appreciate facial anatomy. The nasolabial fold is not an abnormal defect; it is a normal human anatomical boundary separating the dynamic cheek (malar) compartment from the upper lip.

Four distinct anatomical mechanisms govern how and why this fold deepens over time:

1. Maxillary Bone Resorption & Piriform Aperture Widening

Underneath the soft tissues, the facial skeleton undergoes continuous remodeling with age. In the midface, the maxilla (upper jaw bone) resorbs and recedes posteriorly and superiorly. Crucially, the piriform aperture (the bony pear-shaped opening of the nasal cavity) widens and recedes. This bony recession removes the skeletal platform that previously supported the base of the nose and the upper third of the nasolabial fold, creating a hollow shadow known anatomically as the fossa piriformis.

2. Descent of the Superficial Malar Fat Pads

The cheek contains distinct superficial and deep fat compartments. With age, the deep medial cheek fat pad deflates, while the superficial malar fat pad loses its structural collagen scaffolding and slides anteriorly and inferiorly under gravitational pull. As this heavy pad descends, it hits a rigid anatomical roadblock: the nasolabial retaining ligament and the facial mimetic musculature. The sliding fat accumulates and hangs over this boundary, creating the physical "bulge" or "overhang" of the fold.

3. Mimetic Muscular Hyperactivity and Tethering

The muscles of facial expression—principally the levator labii superioris, levator labii superioris alaeque nasi (LLSAN), and zygomaticus major and minor—originate on the facial bones and interweave directly into the dermis of the upper lip and nasolabial crease. Every time you smile, laugh, or speak, these muscles pull the lip upward and outward, repeatedly creasing the overlying skin at the exact line of the retaining ligament.

4. Dermal Thinning and Elastin Degradation

Intrinsic chronological aging and extrinsic ultraviolet photodamage degrade dermal collagen types I and III and fragment elastic fibers. As the dermis loses its tensile strength and recoil capacity, what began as a dynamic fold (visible only during smiling) becomes etched into a permanent, static line present even when your face is completely relaxed.

---

The Regulatory Proving Ground: 16 FDA Premarket Approval (PMA) Families

In the United States, medical devices and injectable dermal fillers are regulated by the FDA's Center for Devices and Radiological Health (CDRH). Unlike generic pharmaceuticals that gain approval through abbreviated pathways, class III injectable devices require rigorous Premarket Approval (PMA) supported by multicenter prospective clinical trials.

The nasolabial fold is the foundational benchmark of modern filler science: 36 approval records across 16 distinct PMA families name correction of moderate-to-severe nasolabial folds among their labeled indications — more than any other single treatment area in filler medicine (for comparison, lip augmentation appears in six filler PMA families in the same database).

Data source: Recomputed from the FDA CDRH Premarket Approval database (accessdata.fda.gov): every PMA whose approval records mention nasolabial folds, deduplicated by PMA number — 36 records collapsing to the 16 families above, verified August 2026.

Every major filler technology used today—from the original high-G' NASHA gels to modern flexible dynamic networks—was proven and validated in clinical trials targeting the nasolabial fold.

---

The Pivotal Trials That Built the Market: What the Data Show

When reviewing filler efficacy, board-certified clinicians rely on published multicenter randomized controlled trials (RCTs). These pivotal studies established how long fillers truly last, how they compare against historical benchmarks, and what objective improvement scores look like.

                    ┌─────────────────────────────────────────┐
                    │      PIVOTAL NLF TRIAL MILESTONES       │
                    └────────────────────┬────────────────────┘
                                         │
    ┌────────────────────────────────────┼────────────────────────────────────┐
    ▼                                    ▼                                    ▼
┌────────────────────────┐   ┌────────────────────────┐   ┌────────────────────────┐
│  NARINS 2003 (n=138)   │   │  BAUMANN 2007 (n=439)  │   │  KAUFMAN-JANETTE 2019  │
│  HA vs Bovine Collagen │   │  Juvederm Pivotal RCT  │   │   64-Week Dynamic RHA  │
└───────────┬────────────┘   └───────────┬────────────┘   └───────────┬────────────┘
            │                            │                            │
            ▼                            ▼                            ▼
 • First US HA approval       • 81%–90% sustained at 6 mo  • 15-month sustained efficacy
 • 56.9% WSRS HA superior     • Up to 88% patient pref     • Dynamic noninferiority
 • Replaced animal collagen   • Established HA standard    • Preserved tissue movement

1. Narins et al. (2003): The Original US Hyaluronic Acid Pivotal RCT

• Citation: Dermatologic Surgery 2003;29(6):588–595 (PMID: 12786700).
• Design: Multicenter, double-blind, randomized, within-subject (split-face) trial comparing non-animal stabilized hyaluronic acid (Restylane) against bovine cross-linked collagen (Zyplast) in 138 patients with bilateral moderate-to-severe nasolabial folds.
• Key Findings: At 6 months post-injection, Restylane was judged superior to collagen on the Wrinkle Severity Rating Scale (WSRS) by independent blinded investigators in 56.9% of patients (versus only 9.5% superior for collagen). On the Global Aesthetic Improvement Scale (GAIS), 62.0% of patients showed superior results with HA at 6 months (versus 8.0% for collagen). This trial ended the era of bovine collagen and established HA as the gold standard for soft-tissue augmentation.

2. Baumann et al. (2007): The Juvéderm Pivotal Multicenter Program

• Citation: Dermatologic Surgery 2007;33(Suppl 2):S128–S135 (PMID: 18086050).
• Design: Randomized, double-blind, multicenter, within-subject clinical trial evaluating cross-linked HA gels (Juvéderm Ultra / Ultra Plus) against bovine collagen in 439 subjects with bilateral nasolabial folds.
• Key Findings: 81% to 90% of HA-treated folds maintained clinically meaningful aesthetic improvement at 6 months or beyond. Furthermore, up to 88% of study participants preferred the HA-treated side over the bovine collagen side.

3. Kaufman-Janette et al. (2019) & Monheit et al. (2020): Resilient HA (RHA) at 64 Weeks

• Citations: Journal of Cosmetic Dermatology 2019;18(5):1244–1253 (PMID: 31444861) and Dermatologic Surgery 2020;46(12):1521–1529 (PMID: 32217842).
• Design: Prospective, multicenter, randomized, evaluator-blinded, split-face comparative trials (n = 140 and n = 174) evaluating resilient hyaluronic acid formulations designed to preserve long HA chains under dynamic facial movement against established cross-linked HA comparators over 64 weeks (15 months).
• Key Findings: Resilient HA demonstrated noninferiority to established comparators in moderate-to-severe nasolabial folds at 24 weeks and sustained high-level correction through 64 weeks of follow-up. Crucially, 3D animated surface imaging confirmed that the flexible matrix stretched and compressed naturally during maximal smiling without creating a rigid, palpable shelf.

4. Active Pipeline Freshness: 128 Registered Clinical Trials

The clinical study of nasolabial folds is not static historical record. A comprehensive audit of clinical trial registries identifies 128 dedicated nasolabial fold clinical trials (90 completed, 16 active/recruiting, and others in pipeline). Ongoing studies include prospective evaluations of novel polycaprolactone biostimulators (such as the Ellansé-S fold trial, NCT06984835) and large-scale real-world observational registries (such as NCT07255261, n = 460), demonstrating continuous refinement in injection technique and polymer longevity.

---

Two Competing Strategies: Direct Fold Injection vs. Midface Support

When you consult an expert aesthetic physician, they will evaluate your face dynamically and recommend one of two distinct treatment strategies—or a customized hybrid of both.

┌─────────────────────────────────────────────────────────────────────────────┐
│                    INJECTION STRATEGY DECISION MATRIX                       │
├──────────────────────────────────────┬──────────────────────────────────────┤
│ STRATEGY A: DIRECT FOLD INJECTION    │ STRATEGY B: MIDFACE / CHEEK SUPPORT  │
├──────────────────────────────────────┼──────────────────────────────────────┤
│ • Best for: Pure structural bone     │ • Best for: Cheek deflation, malar   │
│   recession at pyriform base, deep   │   fat descent, heavy folding caused  │
│   shadow with minimal cheek descent. │   by sliding midface tissues.        │
│ • Technique: Deep supraperiosteal    │ • Technique: Deep boluses on malar   │
│   bolus in pyriform fossa, or linear │   bone (Zygomatic arch / ZMC) to     │
│   fanning in deep subcutaneous plane.│   anchor and lift the cheek vector.  │
│ • Syringe Count: Typically 1 syringe │ • Syringe Count: 1–2 syringes in     │
│   (0.5 mL to 1.0 mL per side).       │   cheeks; 0.5–1 syringe in fold.     │
│ • Advantage: Immediate local shadow  │ • Advantage: Restores natural midface│
│   effacement; cost-efficient.        │   triangle; avoids heavy "snout."    │
│ • Failure Mode: If overfilled, can   │ • Failure Mode: Requires higher      │
│   create a puffy, monkey-like mouth. │   volume; won't erase etched skin.   │
└──────────────────────────────────────┴──────────────────────────────────────┘

Strategy A: Direct Fold Injection (Deep Pyriform & Subdermal Layering)

• Anatomical Target: The deep pyriform space (just lateral to the nasal ala) and the deep subcutaneous fat layer beneath the crease.
• The Technique: The injector places a firm, high-elasticity (high-G') filler directly onto the periosteum of the maxilla at the pyriform aperture. This acts as a structural "tent pole," pushing the recessed bony base forward and immediately softening the deep shadow at the top of the fold. If superficial dermal lines remain, a softer, lower-viscosity filler is layered superficially using a retrograde linear threading technique.
• Ideal Candidate: Younger patients (20s to early 40s) or patients with genetic midface retrusion who have firm skin elasticity and no significant cheek sagging.

Strategy B: Midface / Lateral Cheek Structural Support (The Indirect "Lift")

• Anatomical Target: The lateral zygomatic arch, the zygomaticomaxillary junction, and the deep sub-orbicularis oculi fat (SOOF).
• The Technique: Rather than placing filler into the crease itself, the injector places structural filler (such as Restylane Lyft or Juvéderm Voluma) onto the zygomatic bone. By restoring lost projection in the upper and lateral cheek, the descended soft tissues are mechanically anchored and redraped, pulling tension across the midface and softening the nasolabial fold without adding weight to the lower face.
• Why Many Injectors Emphasize Midface First: A long-standing clinical teaching — particularly visible in Asian-practice literature, where anterior overfilling on wider facial skeletons is a named failure mode — is to restore lateral and deep malar support before deciding how much the fold itself still needs. Treating the cause of the shadow can soften the fold enough that less product is required directly in the crease, avoiding the heavy anterior "snout" that direct packing creates. How much fold filler midface support actually saves varies by patient and has not been quantified in controlled trials; it is a treatment philosophy with anatomical logic behind it, not a measured percentage.

---

Vascular Safety: The Facial Artery Danger Zone

The nasolabial fold carries one of the highest vascular complication risks in facial aesthetics. Understanding the precise three-dimensional path of the facial artery is why patients should seek out experienced medical specialists who understand depth planes.

                    ┌─────────────────────────────────────────┐
                    │      FACIAL ARTERY ANATOMY METRICS      │
                    └────────────────────┬────────────────────┘
                                         │
          ┌──────────────────────────────┴──────────────────────────────┐
          ▼                                                             ▼
┌───────────────────────────────────┐         ┌───────────────────────────────────┐
│     AT ORAL COMMISSURE LEVEL      │         │        AT NASAL ALAR LEVEL        │
└─────────────────┬─────────────────┘         └─────────────────┬─────────────────┘
                  │                                             │
                  ▼                                             ▼
• Distance Lateral: 15.3 ± 3.7 mm             • Distance Lateral: 6.7 ± 4.4 mm
• Depth Beneath Skin: 11.1 ± 3.1 mm           • Depth Beneath Skin: 11.6 ± 3.7 mm
• Artery Diameter: ~2.6 mm                    • Artery Diameter: ~1.9 mm
• Plane: Deep to zygomaticus / risorius       • Plane: Subcutaneous / Angular branch

Quantified Cadaveric & CTA Anatomy

In rigorous soft-tissue anatomical studies:

• Phumyoo et al. (2014, PMID: 25098578): Dissections across 14 soft-embalmed cadaveric specimens revealed that at the level of the oral commissure (mouth corner), the facial artery lies 15.3 ± 3.7 mm lateral to the commissure at a depth of 11.1 ± 3.1 mm with a mean vessel diameter of 2.6 mm. As the artery ascends toward the nasal ala, it angles inward, coursing as close as 6.7 ± 4.4 mm from the nasal ala at a depth of 11.6 ± 3.7 mm (diameter ~1.9 mm).
• Peng et al. (2024, PMID: 38872060): Lead-oxide CT angiography in 52 Asian cadavers mapped three different facial-artery course types relative to the fold (the most common type in 83.7% of sides). Because the artery's path varies this much from face to face, the authors recommend bracketing it — supraperiosteal placement for the upper third of the fold and a superficial dermal-layer technique for the lower two thirds.

The Mechanics of Vascular Occlusion

If a sharp needle or cannula penetrates the facial artery and filler gel is injected into the vessel lumen:

1. Local Ischemia & Necrosis: Embolized gel blocks downstream arterial blood flow, leading to immediate capillary starvation. Untreated, this causes full-thickness skin and cartilage necrosis of the nasal wing (ala) and upper lip.
2. Retrograde Embolic Blindness: If high injection pressure is applied, filler particles can be forced backward against systolic arterial pressure up the angular artery, into the dorsal nasal and ophthalmic arteries, and finally into the central retinal artery. This produces immediate, irreversible blindness in the ipsilateral eye.

Critical Signs of Vascular Compromise

If you receive nasolabial fold filler, watch for these emergency red flags:

• Immediate Blanching: The skin over the lip or nose turns stark white or chalky within seconds of injection.
• Pain Out of Proportion: Severe, sharp, throbbing, or burning pain that persists well beyond typical injection discomfort.
• Livedo Reticularis: A violaceous, dusky, mottled purple net-like discoloration appearing 12 to 24 hours post-treatment.

If any of these signs appear, emergency high-dose pulsed hyaluronidase (typically 500 to 1,500+ units) must be flooded into the affected tissue immediately to dissolve the HA embolus and restore microvascular perfusion.

---

What Filler Cannot Fix: The Laxity Ceiling and "Pillow Face"

One of the most important rules in facial aesthetics is knowing when to stop injecting filler. When patients continue to chase complete eradication of a fold caused by tissue laxity, they encounter the "filler trap."

┌─────────────────────────────────────────────────────────────────────────────┐
│                 WHEN FILLER WORKS VS. WHEN SURGERY IS NEEDED                │
├──────────────────────────────────────┬──────────────────────────────────────┤
│ FILLER IS THE CORRECT TOOL           │ SURGERY / LIFTING IS REQUIRED        │
├──────────────────────────────────────┼──────────────────────────────────────┤
│ • Mild-to-moderate fold depth        │ • Severe, heavy skin overhang        │
│ • Preserved skin elasticity & snap   │ • Skin pinch test >1.5–2.0 cm        │
│ • Deficit driven by bony recession   │ • Prominent jowls & blunt jawline    │
│ • Cheek soft tissues remain elevated │ • Descent of entire SMAS layer       │
│ • Goal: Soften shadow, look rested   │ • Goal: Reposition descended tissues │
└──────────────────────────────────────┴──────────────────────────────────────┘

The "Pillow Face" & Overfilled Mouth Syndrome

When a patient has significant skin laxity and descended cheek fat, the fold is not an empty ditch waiting to be filled—it is an anatomical cliff created by falling tissue.

If an injector injects 3, 4, or 5 syringes of filler directly into this fold in an attempt to make the skin flush with the cheek:

• The natural distinction between the cheek and lip is obliterated.
• The perioral area becomes unnaturally convex, creating a simian (ape-like) or canine "muzzle" appearance.
• During smiling, the excessive filler bolus cannot compress naturally, creating distorted, frozen cheek movement and pushing filler laterally into the buccal space (filler migration).

The Surgical Alternative: Deep Plane Facelift

When soft-tissue laxity dominates, true rejuvenation requires vertical repositioning of the fallen anatomical layers rather than inflation. A modern extended SMAS or deep plane facelift releases the zygomatic and masseteric retaining ligaments, elevates the descended malar fat pad vertically back over the zygomatic bone, and redrapes excess skin without tension. This naturally smooths the nasolabial fold from above, restoring a youthful midface contour that no amount of injectable gel can replicate. For broader context on lower face surgical planning, see our guide to facelift options and recovery.

---

Procedural Costs, Longevity, and Annual Maintenance Math

Budgeting for nasolabial fold correction requires looking past the single-syringe quote and evaluating total multi-year maintenance costs.

Procedure Statistics Context

According to the American Society of Plastic Surgeons (ASPS) 2023 procedural statistics report, roughly 5.29 million hyaluronic acid filler procedures were performed in the United States, up 8% from about 4.88 million the prior year — and HA accounted for about 85% of all filler volume (the non-HA side of the ledger, 924,549 procedures, covers Radiesse, Sculptra, Bellafill, and Renuva). One methodology note: ASPS's 2023 report extrapolated to national estimates, while its 2024 report switched to counting verified member-surgeon patients only (5,331,426 HA filler patients) — so the two years are not directly comparable.

Realistic Pricing and Syringe Math

Cost ranges reflect national averages across dermatology and plastic surgery practices. Pricing varies significantly by geographic region, product brand, and injector credentials.

Why Touch-Up Math Matters

Because hyaluronic acid is naturally degraded by endogenous hyaluronidase enzymes and mechanical shear stress, filler does not disappear overnight. Most patients do not require a full 2-syringe re-treatment every year. Instead, after an initial full correction (e.g., 2 syringes), maintaining the result typically requires a single "touch-up" syringe every 12 to 14 months. For comparing non-surgical options against permanent solutions, see our biostimulators vs HA fillers analysis and Bellafill permanent filler guide.

---

Skin of Color (Fitzpatrick IV–VI) Considerations

Patients with richly pigmented skin (Fitzpatrick skin phototypes IV, V, and VI) have specific anatomical and physiological characteristics that influence nasolabial fold treatment:

Advantages: Thicker Dermis & Slower Bone Resorption

• Enhanced Structural Scaffolding: Skin of color generally features a thicker, more compact dermis with higher fibroblast activity and increased lipid content. This structural density provides superior natural support, often delaying the onset of superficial dermal creasing by a decade compared to Fitzpatrick I–II skin.
• Cheek Architecture: Patients of African, Hispanic, and Asian descent often maintain strong malar projection, meaning nasolabial fold deepening is more frequently driven by localized pyriform aperture hollowing rather than widespread cheek collapse.

Clinical Risks & Safety Guardrails

1. Post-Inflammatory Hyperpigmentation (PIH): Any physical trauma to melanocyte-rich skin can trigger excess melanin production, leaving dark, persistent brown streaks along the nasolabial fold. To minimize PIH risk:
   • Expert injectors favor a single entry point using a blunt-tipped microcannula (25G or 27G) rather than multiple sharp needle punctures.
   • Aggressive superficial dermal fanning or rapid high-pressure injections should be avoided.
2. Keloid and Hypertrophic Scarring: While true keloid formation from subcutaneous filler injection is extremely rare, patients with a documented personal or familial history of keloid scarring must be treated with minimal skin punctures and cold compress protocols.
3. Product Selection: Colorless, pure hyaluronic acid gels with low inflammatory potential are preferred. High-shear biostimulators that require vigorous post-injection massage should be used cautiously to avoid inflammatory dyschromia.

---

The Non-Filler Shelf: Microneedling, Energy Devices, Threads, and Fat

For patients who prefer not to use synthetic dermal fillers or who have reached the structural limit of what fillers can accomplish, several alternative modalities exist:

┌─────────────────────────────────────────────────────────────────────────────┐
│                    THE NON-FILLER TREATMENT SPECTRUM                        │
├───────────────────────┬──────────────────────┬──────────────────────────────┤
│ MODALITY              │ EVIDENCE GRADE       │ REALISTIC CLINICAL BENEFIT   │
├───────────────────────┼──────────────────────┼──────────────────────────────┤
│ Microfocused          │ Moderate             │ Mild lifting of cheek tissue;│
│ Ultrasound / RF       │ (Level II Evidence)  │ tightens dermis; does not    │
│ (Ultherapy / Sofwave) │                      │ restore deep structural fat. │
├───────────────────────┼──────────────────────┼──────────────────────────────┤
│ PDO / PLLA / PCL      │ Low-to-Moderate      │ Immediate mechanical pull    │
│ Suspension Threads    │ (Level III Evidence) │ lasting 4–9 months; risk of  │
│                       │                      │ puckering, asymmetry, snap.  │
├───────────────────────┼──────────────────────┼──────────────────────────────┤
│ Autologous Fat        │ High                 │ Permanent living volume;     │
│ Grafting (Fat Transfer│ (Level II Evidence)  │ variable graft take (40–70%);│
│                       │                      │ requires surgical harvest.   │
├───────────────────────┼──────────────────────┼──────────────────────────────┤
│ Topical Skincare      │ Low (for folds)      │ Hydrates surface epidermis;  │
│ (Retinoids, Peptides) │ (Level I for aging)  │ zero effect on deep fat or   │
│                       │                      │ skeletal bone recession.     │
└───────────────────────┴──────────────────────┴──────────────────────────────┘

• Energy-Based Skin Tightening (Ultrasound / Radiofrequency): Devices like microfocused ultrasound (Ultherapy) or high-intensity fractional ultrasound (Sofwave) deliver thermal coagulation points to the deep dermis and SMAS layer. They stimulate neocollagenesis to mildly tighten loose cheek skin, making them useful adjuncts for mild laxity, but they cannot replace 2 mL of lost structural volume. For deeper comparison of device technologies, see our review of non-surgical facelift devices.
• Suspension Thread Lifts (PDO / PLLA): Barbed threads anchored in the temporal fascia can mechanically pull the descended malar fat pad upward. However, clinical duration is modest (typically 6 to 12 months before tensile degradation), and threads carry risks of visible palpability, skin puckering, and thread extrusion. For lower face comparisons, review our marionette lines treatment guide.
• Autologous Fat Transfer: Living fat cells harvested from the abdomen or thighs can be purified and micro-injected into the deep pyriform space and midface. Unlike HA fillers, successful fat grafts establish permanent vascularization. However, graft survival varies (typically 40% to 70% retention), requiring skilled surgical execution and occasional secondary touch-ups. To compare fat against synthetic implants and fillers, see our flat cheeks volume restoration guide.

---

At-Home and "Natural" Claims: Why Facial Exercises Do Not Fix Folds

A recurring question on search engines and social media is whether facial exercises ("face yoga"), jade rollers, or cosmetic facial massage can lift nasolabial folds naturally. Major consumer health portals occasionally repeat these suggestions without examining clinical evidence.

The published clinical trial record reveals a clear answer:

In the only randomized clinical trial evaluating facial exercise programs for aging appearance (Alam et al., 2018, JAMA Dermatology; PMID: 29299598), 27 middle-aged women underwent an intensive 20-week facial exercise protocol consisting of 32 distinct muscle resistance movements performed for 30 minutes daily or every other day.

When independent blinded dermatologists evaluated photographic outcomes using validated rating scales:

• Upper and lower cheek fullness scores improved significantly (P = 0.003).
• However, at-rest nasolabial fold scores showed ZERO statistically significant change (P > 0.99).

Physiologically, this makes complete sense: nasolabial folds are created and deepened by the repetitive contraction of facial mimetic muscles pulling on the dermal retaining ligaments. Exercising and bulking those exact muscles simply increases the dynamic force pulling the crease inward. While facial exercises are free and harmless for general facial muscle tone, claiming they can lift or eliminate a structural nasolabial fold is scientifically unsupported. For an in-depth breakdown of the entire facial exercise literature, see our dedicated review of does face yoga work.

---

Frequently Asked Questions (FAQ)

How much does nasolabial fold filler cost?

Most patients require between 1 and 2 syringes of hyaluronic acid filler for complete correction. Based on national averages, a single syringe ranges from $650 to $950, making a typical initial treatment cost between $650 and $1,900. If midface cheek support is required simultaneously to lift heavy folds, 2 to 3 total syringes may be recommended ($1,600 to $2,600).

Can nasolabial fold filler be dissolved if I don't like it?

Yes, provided you received a hyaluronic acid filler (such as Juvéderm, Restylane, Belotero, or RHA). An enzyme called hyaluronidase can be injected directly into the fold to break down and dissolve the filler within 24 to 48 hours. Non-hyaluronic biostimulators (Sculptra, Radiesse) and permanent fillers (Bellafill) cannot be dissolved with hyaluronidase.

How long does filler in the smile lines last?

In modern clinical practice, HA fillers in the nasolabial fold typically last between 9 and 18 months. Products formulated with high cross-linking or resilient long chains (such as RHA 4, Juvéderm Vollure, or Restylane Defyne) routinely demonstrate sustained aesthetic improvement at 12 to 15 months in clinical trials. Longevity depends on your individual metabolic rate, product selection, and whether the filler was placed in deep structural fat versus superficial dynamic planes.

Does injecting smile lines hurt?

Discomfort is generally mild to moderate. Almost all modern FDA-approved fillers are pre-mixed with 0.3% lidocaine (a local anesthetic), which numbs the treatment area from the inside within seconds of the first injection. Additionally, providers typically apply a topical compounded numbing cream (such as 23% lidocaine / 7% tetracaine) for 20 to 30 minutes prior to injection. Using a blunt microcannula further reduces pain and needle pricks.

Can Botox be used for nasolabial folds?

No. Botulinum toxin (Botox) is a neuromodulator that temporarily relaxes muscles; it does not fill hollows or restore lost volume. Injecting Botox into the primary muscles surrounding the nasolabial fold (the zygomaticus and levator muscles) would weaken your upper-lip elevators, producing a flat, asymmetric smile and altered lip control during speech. Chewing itself is unaffected — these are expression muscles, not chewing muscles — but the smile distortion alone is why injectors do not treat the fold with toxin. For a comprehensive comparison of when to use toxins versus fillers across different facial zones, see our guide to Botox vs filler.

What should I avoid immediately after getting NLF filler?

For the first 24 to 48 hours post-injection, avoid:

• Strenuous exercise, heavy weightlifting, and inversions (yoga/pilates);
• High heat environments (saunas, steam rooms, hot tubs, direct intense sun);
• Touching, pressing, or aggressively massaging the treated folds;
• Dental procedures or routine dental cleanings for 2 to 4 weeks (to minimize bacterial seeding and late-onset biofilm or nodule formation);
• Alcohol and blood-thinning supplements (fish oil, high-dose vitamin E, NSAIDs) for 24 hours to reduce bruising.

---

Sources

1. Narins RS, Brandt F, Leyden J, et al. A randomized, double-blind, multicenter, comparison of the efficacy and tolerability of Restylane versus Zyplast for the correction of nasolabial folds. Dermatol Surg. 2003;29(6):588-595. PubMed
2. Baumann LS, Shamban AT, Lupo MP, et al. Comparison of smooth-gel hyaluronic acid dermal fillers with cross-linked bovine collagen: a multicenter, double-masked, randomized, within-subject study. Dermatol Surg. 2007;33(Suppl 2):S128-S135. PubMed
3. Phumyoo T, Tansatit T, Rachkeaw N. The soft tissue landmarks to avoid injury to the facial artery during filler and neurotoxin injection at the nasolabial region. J Craniofac Surg. 2014;25(5):1885-1889. PubMed
4. Peng T, Yu H, Hong WJ, et al. Three-Dimensional Location of the Facial Artery in Relation to the Nasolabial Fold in Asian People: A Cadaveric CTA Study. Aesthetic Plast Surg. 2024;48(20):4077-4085. PubMed
5. Kaufman-Janette J, Taylor SC, Cox SE, et al. Efficacy and safety of a new resilient hyaluronic acid dermal filler, in the correction of moderate-to-severe nasolabial folds: A 64-week, prospective, multicenter, controlled, randomized, double-blind and within-subject study. J Cosmet Dermatol. 2019;18(5):1244-1253. PubMed
6. Monheit G, Kaufman-Janette J, Joseph JH, et al. Efficacy and Safety of a Resilient Hyaluronic Acid Dermal Filler, RHA 4, in the Treatment of Moderate-to-Severe Nasolabial Folds: A 64-Week, Prospective, Multicenter, Controlled, Randomized, Evaluator-Blinded, Split-Face Study. Dermatol Surg. 2020;46(12):1521-1529. PubMed
7. Alam M, Walter AJ, Geisler A, et al. Association of Facial Exercise With the Appearance of Aging. JAMA Dermatol. 2018;154(3):365-367. PubMed Central
8. U.S. Food and Drug Administration (FDA). Premarket Approval (PMA) Database: Soft Tissue Fillers. FDA CDRH
9. American Society of Plastic Surgeons (ASPS). 2023 Plastic Surgery Procedural Statistics Report: Dermal Fillers. ASPS Dermal Fillers